2025 brought no shortage of new ideas in Washington to reshape how the United States pays for medicines. From Most Favored Nation  (MFN) proposals to executive actions and broader drug pricing reforms, the policy debate moved quickly, with major implications for patients, investors, and the future of biomedical innovation.  Throughout the year, Incubate stayed at the cutting edge of that dialogue, bringing a consistent focus to what matters most: protecting access today while

WASHINGTON (December 19) –   Today, the Center for Medicare and Medicaid Innovation (CMMI) announced a proposed series of Medicare drug pricing demonstrations affecting some Part B  and Part D  medicines, respectively. The Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) demonstrations would significantly restructure Medicare drug reimbursement and coverage, pegging Medicare Part B and Part D drug prices to those

This month, Incubate executive director John Stanford's conversation with Senator Thom Tillis (R-NC) on the Making Medicine Podcast  was featured in RealClearHealth , IAM Media , and IP Watchdog . Sen. Tillis called for aggressive measures to counter China's growing economic influence, particularly in life sciences innovation, highlighting the need to pass the Patent Eligibility Restoration Act to address what he described as the current law's chilling effect on innovation: "

Incubate executive director John Stanford recently discussed how Congress is reshaping biotechnology policy on an episode of the Making Medicine podcast . The conversation focuses on the 2025 National Defense Authorization Act (NDAA), Congress's annual defense bill, and its emphasis on biotechnology as a national security priority. Stanford explains how the NDAA treats biotech as a strategic capability, with provisions that strengthen domestic biomanufacturing, supply chain r

WASHINGTON ( December 2 ) -- Yesterday, the United States and the United Kingdom announced  a new agreement on pharmaceutical pricing as part of the Economic Prosperity Deal (EPD). The agreement is expected to increase the U.K.'s valuation of new medicines and expand its long-term investment in innovative therapies. The United States, in turn, committed to exempt U.K.-origin pharmaceuticals from any future Section 232 tariffs and to refrain from targeting U.K. pricing polici

WASHINGTON ( November 26) -- Yesterday, the Trump administration announced Maximum Fair Prices (MFPs) for the next 15 Medicare Part D drugs selected for price setting under the Medicare Drug Price Negotiation Program. The new prices take effect in January 2027.   Incubate's executive director, John Stanford, issued the following statement in response to the announcement:   " Today's announcement is another reminder of the fundamental flaws in existing federal drug-pricing p